The roles of angiogenesis and angiogenic factors after allogenic hematopoietic SCT (HSCT) and during acute GVHD (aGVHD) are not known. Studies on pediatric patients are extremely scarce. Levels of angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) were analyzed from blood samples of 67 consecutive patients. The levels were correlated with aGVHD grades, routine laboratory parameters and outcome. Pre-transplant Ang2 values correlated with the occurrence of intestinal aGVHD (P ¼ 0.009), whereas post-transplant measurements correlated with the severity of skin and liver aGVHD (P ¼ 0.03, P ¼ 0.04, respectively). Pre-transplant levels of VEGF were associated with the occurrence of skin aGVHD (P ¼ 0.04), whereas post-transplant levels correlated to the severity of intestinal aGVHD (P ¼ 0.04). High Ang2 levels were associated with shorter EFS (P ¼ 0.039) and increased non-relapse mortality (NRM) (P ¼ 0.009). In conclusion, higher Ang2 levels predict higher NRM and, with coexisting high VEGF, also shorter EFS after pediatric HSCT. Our results suggest that both pre-and post-transplant levels of Ang2 and VEGF seem to correlate to the clinical state of the patient. However, the pathophysiology of this connection needs further studies.
INTRODUCTION
Despite major developments in the field of allogeneic hematopoietic SCT (HSCT), the treatment is still associated with considerable complications and late effects. In addition to relapses and serious infections, the main cause of mortality and morbidity after allogeneic HSCT is GVHD. Once fully developed, it is difficult to treat, and prophylaxis and early diagnosis are crucial for a favorable outcome. However, the diagnosis is currently mainly based on clinical findings. There are no specific, easily applicable markers.
The significance of angiogenesis in the growth and spread of solid tumors is well established. It is also known that BM angiogenesis is increased in hematological malignancies. [1] [2] [3] Angiogenesis is regulated by promoting and inhibiting angiogenic growth factors. 1 Vascular endothelial growth factor (VEGF) has widespread effects on tumor progression by enhancing tumor cell survival and differentiation. 4 Another essential group of angiogenesis-related factors is the angiopoietin family and its receptors Tie-1 and Tie-2. Angiopoietin-2 (Ang2) is an inhibitor of the pro-angiogenic angiopoietin-1, but it can also function as an angiogenesis-promoting agent, depending on the cytokine milieu. When expressed together with VEGF, Ang2 enhances angiogenesis. 5 VEGF and angiopoietins are the two most important angiogenic factors and therefore they were analyzed in this study.
Studies of angiogenesis in the transplantation context are new and contradictory. According to the study of Chen et al., 6 the connection between VEGF and transplant-related immunology showed that corneal transplantation in mouse after inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3) resulted in significantly reduced movement of dendritic cells to lymph nodes. According to a few more recent studies, angiogenic factors may have a connection to GVHD. [7] [8] [9] However, majority of these studies in adults and may not be directly applicable to children. 10 The aim of this study was to explore the significance of angiogenic factors in pediatric patients after allogeneic HSCT. We used two time points, days 21 and 100 after transplantation, which are important and widely used time points in studying the posttransplantation period. Day 21 expresses early postengraftment and preGVHD status, and day 100 is a commonly used milestone for early non-relapse mortality (NRM), also being the timely transition between acute (aGVHD) and chronic GVHD. Our hypothesis was that these time points could reveal information about connection between angiogenic factors and both GVHD and survival. We studied angiogenic factor levels before the cell infusion and on days 21 and 100 covering different types and grades of GVHD. Our end points, EFS, NRM and cumulative incidence of relapse, were related to Ang2 and VEGF levels.
PATIENTS AND METHODS Patients
This study is based on the analysis of plasma samples, routine blood values and hospital records of 67 consecutive children who underwent HSCT at the Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki, Finland. This was a prospective study with samples collected specifically for this study. Out of 72 consecutive patients, five were excluded due to lack of samples. Fifty-nine patients received TBI of 10-12 Gy in 5-6 fractions and four patients were irradiated with 4.5 Gy on lymph node regions. Patient characteristics are given in Table 1 . The study was approved by the Ethical Committee of Pediatrics and Psychiatry at the Helsinki University Central 1 Hospital, and informed consent was obtained from the parents and age-appropriate patients.
All study patients underwent allogeneic transplantation, but two patients had received an auto-SCT before the allogeneic one. One patient was first diagnosed with Hodgkin's disease, treated using autologous HSCT, and later on developed secondary AML, for which the patient received an allogeneic SCT after a two-year interval. The second patient had anaplastic large-cell lymphoma and received two auto-SCTs, with the allogeneic SCT taking place 2.5 months after the second autologous HSCT.
Sixty-two patients received one allogeneic HSCT. Five patients received two or three grafts of which three were given within 100 days of the first transplantation. If multiple SCTs were performed, only the first allogeneic one was taken into account in this analysis.
The most commonly utilized stem cell source was unrelated donor BM (34 patients). Ten patients received unrelated cord blood, and one a combination of unrelated cord blood and CD34 þ selected 'third party' cells from the father. Nineteen donors were HLA-identical siblings, and three were haploidentical parents. Three patients received additional DLI within the first 100 days after transplantation.
The GVHD status between day 0 and day 100 was assessed for each organ (skin, liver and intestine) separately. The overall GVHD grade was assessed based on the 1994 Keystone Consensus Criteria. 11 Clinical data were collected from the hospital records. The highest grade specific for each target organ was taken into account. Routine laboratory parameters (hemoglobin, platelet, leukocyte, monocyte and neutrophil counts, IgE, and CRP) were registered on days 0, 21 and 100. If multiple tests had been taken on the same day, the morning value was registered.
Laboratory methods
Venous blood was drawn from the central venous catheter before the day of the SCT (day 0 sample) and on days 21 and 100 after the transplantation. Analysis of the angiogenic factors Ang2 and VEGF was performed by ELISA according to the instructions of the manufacturer (R&D Systems, Minneapolis, MN, USA). This assay measures VEGF 165 isoform levels. These analyses were performed on plasma, not serum, to inhibit the release of angiogenic factors from platelet granules during clotting. The detection limit of VEGF was 31.2 pg/mL, which was used for the negative values. 
Conditioning therapy Information missing from one patient.
c One patient received a combination transplant, of which one was CMV positive and the other CMV negative (not included in the table).
Ang2 and VEGF levels in transplanted children M Porkholm et al
All samples were analyzed at the same time. Analyses and calibrations were performed in duplicate from frozen plasma. Concentrations were determined without knowledge of clinical data. Intraassay variability was assessed by analyzing two replicates of 15 serum samples, and the interassay variation was assessed by assaying 15 samples twice in two separate assays. Both intraassay and interassay variations were o10%. Day 0 sample was available from 67/67, day 21 sample from 64/67 and day 100 sample from 60/67 patients. The median day for taking the day 0 sample was À 7 (range day À 106 to day 0). All day 21 samples were taken within two days' range around the median (median 21, range 19-22; s.e.m. 0.068). Out of 67 patients, 60 had a day 100 sample (median 98, range 67-148; s.e.m. 2.940).
Statistical methods
The data were analyzed with SPSS Version 15.0 Software and PASW Statistics version 18.0 and 20.0 (SPSS, Chicago, IL, USA). Mann-Whitney UTest, Spearman Correlation, Kaplan-Meier Survival analyses, 12 Anova and GEE analysis were used. Log Rank test was used in the comparisons. 13 Clinical data were collected until day 100 except for relapse and survival data, which were analyzed until the end of the follow-up. Median duration of the follow-up was 29 months (range 3-48 months). EFS was defined as the time from the date of transplantation to the documented event (relapse or death). Non-relapse mortality was defined as the cumulative incidence of death as a result of toxicity. EFS, NRM and cumulative incidence of relapse were analyzed during the whole follow-up time by dividing the patients into two or three groups based on the levels of Ang2 and VEGF (either to two groups according to median or to three groups by percentiles: 0-25 percentile, 25-75 percentile and 75-100 percentile). In each group, an event was defined as death or relapse after the SCT.
RESULTS
We analyzed Ang2 and VEGF levels of 67 consecutive children who underwent HSCT. Out of 67 study patients, 22 died during the follow-up; 14 patients were diagnosed with relapse after HSCT, and five patients died of severe GVHD. Three patients died of other causes: pneumonia (n ¼ 1), acute respiratory distress syndrome (n ¼ 1) and toxic reactions (n ¼ 1). The day 100 NRM was 4.5% (3/67), and the day 200 NRM was 16% (11/67). The cumulative incidence of relapse was 7.5% (5/67) on day 100, 19.4% (13/67) at one year and 20.9% (14/67) at two years post transplant.
Ang2 and VEGF levels The Ang2 and VEGF levels are shown in Figure 1 (Supplementary Table S1 ). Two values were exceptionally high. One was the Ang2 value of day 21, over ten times higher than the median value, analyzed from a girl with T-ALL. She died 47 days after the transplantation with severe GVHD of the gastrointestinal tract and liver. The other was Ang2 on day 100, almost seven times higher than the median, from a boy with precursor B-ALL. He died 14 months after the transplant due to relapse. Ln(Ang2) increased during the follow-up (time effect Po0.001, ANOVA for repeated measures), whereas Ln(VEGF) levels were constant from day 0 to 21, but increased from day 21 to 100 (time effect P ¼ 0.025, ANOVA for repeated measures). The Ang2 and VEGF levels were also analyzed separately in each diagnostic group (Supplementary  Table S1 ). For Ang2, there was a rising trend in the largest diagnostic groups (Figure 2) .
Influence of stem cell source on angiogenic factors The levels of angiogenic factors were analyzed in relation to the stem cell source. No difference was found between the stem cell source and either of the angiogenic factors (GEE analysis, P ¼ 0.3 Ang2; P ¼ 0.17 VEGF dicotomized) Effect of irradiation on angiogenic factors The majority of the study patients received TBI as part of their conditioning (N ¼ 59), and only four patients were treated with total nodal irradiation. The numbers of patients who only received nodal or no irradiation was very small, which makes statistical comparisons irrelevant.
Effect of engraftment on angiogenic factors Engraftment, defined as the day when the neutrophil count exceeded 0.5 Â 10 9 /L after HSCT, also correlated with the levels of angiogenic factors. The median day of engraftment was 17. No connection to angiogenic factor levels was found.
Angiogenic factors and acute GVHD Out of the 67 patients, 44 had GVHD during the first 100 days after HSCT (Table 2 ). Clinically symptoms represented aGVHD. The total aGVHD grade was I in 11, II in 6, III in 22, and IV in 5 patients. Patients with GVHD had higher VEGF levels on day 0 compared with patients who did not have aGVHD (P ¼ 0.025). Concerning Ang2 levels, no difference was found.
Patients with intestinal GVHD had lower Ang2 levels on day 0 (P ¼ 0.009) (Figure 3a) . On day 100, higher Ang2 was associated with the severity of skin GVHD (P ¼ 0.03) and liver GVHD (P ¼ 0.04) (Figure 3a ). Higher VEGF on day 0 correlated with the later occurrence of skin GVHD (P ¼ 0.04), and on day 21 with the later severity of intestinal GVHD (P ¼ 0.04) (Figure 3b) . GVHD severity correlated with EFS. Severe GVHD (grade 3-4) was associated with a shorter survival (skin GVHD: P ¼ 0.008; intestinal GVHD: P ¼ 0.034 and liver GVHD: P ¼ 0.003). 
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No correlation between GVHD occurrence and age of the patient, type of diagnosis or stem cell source was found.
Angiogenic factors and survival
In the Kaplan-Meier survival analysis, neither Ang2 nor VEGF alone correlated with EFS. To study the effects of Ang2 parallel with high VEGF levels, patients were divided into two groups based on the median VEGF value. This was done separately for values of day 0, day 21 and day 100. When patients in the group with high VEGF values on day 100 were analyzed, Ang2 levels above median reflected a worse prognosis (P ¼ 0.039) (Figure 4 ). Non-relapse mortality and cumulative incidence of relapse were analyzed by dividing the patients into three categories according to their angiogenic factor levels. We found an association between higher NRM and Ang2 levels (P ¼ 0.036 on day 21, P ¼ 0.009 on day 100) (Figure 5 ), but none between the angiogenic factors and the cumulative incidence of relapse. No association was found between VEGF levels and NRM.
Angiogenic factors and laboratory values
Correlations between the routine laboratory values (Hb, WBC, monocytes, neutrophils, platelets, IgE and CRP) and angiogenic factors were also analyzed. No relevant associations were found (data not shown).
DISCUSSION
In this study, we correlated the angiogenic factors Ang2 and VEGF with multiple transplant-related factors in 67 consecutive pediatric patients undergoing allogenic HSCT. As far as we know, this is the first study concerning angiogenic factors after HSCT in pediatric patients only. The time points day 0 and 21 were chosen to be predictive for GVHD, and day 100 to give information about the association between present GVHD and angiogenic factor levels. In our data, there was a trend to increasing Ang2 levels from day 0 through day 21 to day 100, whereas the levels of VEGF did not show remarkable changes. Higher VEGF levels on day 0 predicted skin GVHD, and on day 21 severe intestinal GVHD. In general, aGVHD symptoms occur later than day 21. Lower pre-transplant Ang2 values predicted the occurrence of intestinal GVHD, but, on the other hand, higher Ang2 levels on day 100 correlated with severe skin and liver GVHD reflecting symptoms present or even resolving. Our main finding was that there was a correlation between higher Ang2 levels and both higher NRM and lower EFS. There was no correlation between angiogenic factor levels and the cumulative incidence of relapse.
Studies of angiogenesis in the transplantation context are new and controversial. Lunn et al. 7 published findings suggesting that the concentration of VEGF is increased in patients with GVHD compared with controls, supporting our findings. However, there are also reports about high VEGF levels and a lower risk of severe aGVHD. 8, 14, 15 In the study of Min et al., 
Abbreviations:
In addition, one patient received a combination transplant consisting of cells from cord blood and one parent.
Ang2 and VEGF levels in transplanted children M Porkholm et al measured on days 0, 7 and 14 were associated with a higher risk for severe GVHD and NRM. The levels of VEGF had an increasing trend on the last day of measurement in the study of Min et al., suggesting that the results might have been more similar to ours if samples had been taken on day 21, as in our study. However, it is noteworthy that the study of Min et al. comprised adults and that the share of AML patients was significantly higher than in our study. Results of these reports differ from ours, but again the patient material was very different, making comparisons difficult. The diagnoses of the patients were not reported in detail. In addition, the samples were serum, not plasma.
Whether the results of angiogenic factor levels are obtained from analysis of serum or plasma is a relevant detail, since serum VEGF levels are significantly higher than VEGF levels retrieved from plasma. This phenomenon is explained by the physiology of VEGF. It is stored in platelet granules and released during analysis of serum samples. VEGF levels measured from serum samples may not reflect the production by peripheral tissues. 16 The impact of Ang2 is unclear. Hou et al. 17 reported that high pre-transplant levels of Ang2 correlated with poor prognosis, but its role as predictor of the OS or nonrelapse mortality is still controversial. 17, 18 According to Kü mpers et al., 18 high pretransplant levels of Ang2 were associated with an unfavorable prognosis, and they suggested that it could function as a marker for the risk of relapse. The median age of the patients was 54 and they were all diagnosed with either AML or myelodysplastic syndrome. No measurements after HSCT were done. Nomura et al. 19 found a correlation between high serum post-transplant Ang2 and cytokine markers of severe GVHD in a patient group consisting mainly of adults and only few children. As in our study, median Ang2 increased with time. Unfortunately, neither did they analyze pediatric patients separately nor state whether Ang2 was analyzed from plasma or serum. In a recent study of Luft et al., 20 Ang2/VEGF was associated with steroid-refractory GVHD. According to their study, endothelial cell vulnerability and dysfunction, rather than refractory T-cell activity, drives treatment refractoriness of GVHD via Ang2, VEGF and thrombomodulin.
The role of Ang2 is complicated by the fact that its effect depends on the VEGF levels, and that the prognostic value is evident only with coexistent high VEGF levels. 17 We therefore also investigated the effect of Ang2 separately in patients with high VEGF values.
In our patients, the median neutrophil engraftment was on day 17, and no connection between engraftment and angiogenic factor levels was found. As far as we know, there are no studies about the behavior of angiogenic markers during engraftment.
We are aware about certain problems in our study. One problem regards the reference values. There are studies about VEGF reference values, but it is difficult to compare serum and our plasma samples, or adult and pediatric patients. In one study, 107 (2-19 years old) healthy children had serum VEGF levels of 241±147 pg/mL (mean±s.d.). 21 According to Bono et al., 22 serum VEGF levels in healthy adults varied between 28 and 850 pg/mL (median 190, n ¼ 63), and serum Ang2 levels between 825 and 24 500 pg/mL (median 2275, n ¼ 46) (Bono et al., unpublished data). There are no published control values for Ang2 levels in pediatric population. Another problem is the possible effect of the conditioning therapy on a proportion of the day 0 samples. The day 0 samples we collected before graft infusion, but, unfortunately, some day 0 sampling was done after the start of conditioning, which may have biased the angiogenic factor levels because of the cytokine release and inflammatory response due to the conditioning.
The pathophysiology of our findings remains so far obscure. Whether angiogenic changes drive GVHD or are a consequence of Ang2 and VEGF levels in transplanted children M Porkholm et al it has not been elucidated. However, both our day 21 and 100 results suggest that higher levels of angiogenic factors predict a poorer prognosis. Signs of GVHD rarely occur before day 21 indicating that this time point may be predictive. Our day 21 and 100 results suggest endothelial dysfunction might be driving force of GVHD. 20 In summary, higher post-transplant Ang2 levels predict higher NRM and, with coexisting high VEGF, also shorter survival after pediatric HSCT. VEGF was predictive of aGVHD, whereas Ang2 on day 100 correlated with existing severe GVHD. The pathophysiology of these correlations merits further studies. 
